Viz.ai, an artificial intelligence (AI) powered healthcare software provider, has raised $50m through Series B funding round to expand its synchronised stroke care.

San Fransisco-based investment firm Greekoaks led the financing round, with participation from Threshold Ventures, CRV and current investors GV and Kleiner Perkins.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

In 2018, the company’s product, Viz LVO, a computer-aided triage and notification software, was given a De Novo clearance by the US Food and Drug Administration (FDA).

The firm uses deep learning algorithms to detect suspected large vessel occlusion, especially the disabling type of stroke, in a CT scan.

Following detection, the stroke team specialist is alerted within minutes, allowing synchronised care and timely treatment.

More than 300 hospitals across the US use Viz.ai’s acute ischemic stroke software.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Viz.ai CEO Chris Mansi said: “Viz.ai’s mission is to improve access to lifesaving treatments. In a stroke, by saving time for the hospital system, we can achieve significant cost savings for the payer and most importantly, improved outcomes for the patient.

“This round of funding will enable us to expand the benefits of Synchronised Care to more disease states and geographies, democratising the quality of health care globally.”

Neil Shah of Greenoaks said: “We see Viz.ai as the future of how healthcare is delivered. With rising costs and more focus on value-based care, there needs to be an emphasis on delivering the highest quality care in the shortest amount of time while reducing costs.”

The company, based in San Francisco and Tel Aviv, also secured 510(k) clearance from the US FDA for its Viz CTP, a tool for automated cerebral perfusion image analysis.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact